# Vivos Therapeutics, Inc. (VVOS) — capital_raise/rights_offering [expired]
Source: SEC API (secapi.ai) · situation sit_bbff97f8ae260a975cba · retrieved 2026-08-11T15:49:19.789Z

## Overview
Vivos Therapeutics, Inc. is a medical device company focused on surgical and medical instruments and apparatus.

On June 30, 2026, Vivos Therapeutics entered into a Securities Purchase Agreement with V-Co Investors 4 LLC and Bigger Capital Fund, LP, selling 3,608,496 units at $0.582 per unit for aggregate proceeds of approximately $2.1 million. Each unit consists of one share of Series A Convertible Preferred Stock (stated value $0.456, convertible 1-for-1 into common stock), warrants to purchase common stock equal to 100% of conversion shares (exercise price $0.456, 5-year term), and two transferable subscription rights per unit. The Company received $1.0 million in cash at closing, with an additional $1.0 million from a prior bridge note automatically converting into the offering. The warrants contain beneficial ownership limitations preventing V-Co 4 and affiliates from exceeding 19.99% ownership and Bigger and affiliates from exceeding 9.99% (or 4.99% at election) of outstanding common stock.

## Terms
- Counterparty: V-Co Investors 4 LLC and Bigger Capital Fund, LP · Deal value: $2.1M · Consideration: mixed · Price/share: $0.582

## Key dates
- Expected close 2026-06-30 · Expired 2026-07-07

## Timeline
- 2026-07-07 · 8-K (0001493152-26-032387): Vivos Therapeutics raises $2.1M PIPE; issues 3.6M preferred units with warrants, subscription rights — *Vivos Therapeutics, Inc. is a medical device company focused on surgical and medical instruments and apparatus.* On June 30, 2026, Vivos Therapeutics entered into a Securities Purchase Agreement with V-Co Investors 4 LLC and Bigger Capital Fund, LP, selling 3,608,496 units at $0.582 per unit for aggregate proceeds of approximately $2.1 million. Each unit consists of one share of Series A Convertible Preferred Stock (stated value $0.456, convertible 1-for-1 into common stock), warrants to purchase common stock equal to 100% of conversion shares (exercise price $0.456, 5-year term), and two transferable subscription rights per unit. The Company received $1.0 million in cash at closing, with an additional $1.0 million from a prior bridge note automatically converting into the offering. The warrants contain beneficial ownership limitations preventing V-Co 4 and affiliates from exceeding 19.99% ownership and Bigger and affiliates from exceeding 9.99% (or 4.99% at election) of outstanding common stock.
  https://www.sec.gov/Archives/edgar/data/1716166/0001493152-26-032387.txt

## Citations
- 0001493152-26-032387 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000149315226032387